Ozmosi | Molgramostim Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Molgramostim

Alternative Names: molgramostim
Clinical Status: Active
Latest Update: 2026-01-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | Chile | China | Germany | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Sweden | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Savara
Company Location: Western America
Company CEO: Matthew Pauls
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Molgramostim

Countries in Clinic: Australia, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Poland, Portugal, Romania, Spain, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 6

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Savara presented P3 Pulmonary Alveolar Proteinosis results on 2025-10-21 for Molgramostim
  • Clinical Outcomes Reported - Savara presented P3 Pulmonary Alveolar Proteinosis results on 2025-09-29 for Molgramostim
  • Clinical Outcomes Reported - Savara presented P3 Pulmonary Alveolar Proteinosis results on 2025-08-21 for Molgramostim

Highest Development Phases

Phase 3: Pulmonary Alveolar Proteinosis

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06431776

aPAP

P3

Not yet recruiting

Pulmonary Alveolar Proteinosis

2027-01-01

11%

2024-05-30

Primary Endpoints|Treatments

2024-512039-66-00

SAV006-04

P3

Not yet recruiting

Pulmonary Alveolar Proteinosis

2027-08-31

2025-04-26

Treatments

2024-511052-41-00

SAV00605

P3

Active, not recruiting

Pulmonary Alveolar Proteinosis

2026-12-31

2025-05-02

Treatments

jRCT2051210036

jRCT2051210036

P3

Recruiting

Pulmonary Alveolar Proteinosis

2024-12-31

NCT04544293

IMPALA-2

P3

Active, not recruiting

Pulmonary Alveolar Proteinosis

2023-11-30

21%

2025-08-08

Primary Endpoints

2020-001263-85

IMPALA-2

P3

Completed

Pulmonary Alveolar Proteinosis

2023-10-19

21%

2025-07-09

Treatments